PureTech Health plc
NASDAQ:PRTCBiotechnology
+$0.45 today
- Market cap
- $423.09M
- Beta
- 0.79
- P/E (TTM)
- -0.4
- EPS (TTM)
- -$45.37
Volume 0.01M
Average 0.01M
PRTC Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
PureTech Health plcNASDAQ: PRTC
Stock-Based Compensation · Q4 FY2025 · quarter ended Dec 2025
Stock-based compensation outflow shrinks to $0
Q4 FY2025 stock-based compensation was $0, compared with $18.2M a year earlier. Over 3 fiscal years it compounded at -17.6% a year.
Context
- Stock-based compensation amounted to 176.5% of revenue in FY2025, down 296.8 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 8.22M USD
- Year-over-year change
- -64.0%
- 4-year CAGR
- -12.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.22M | -64.0% |
| FY2024 | 2024-12-31 | 22.85M | +417.6% |
| FY2023 | 2023-12-31 | 4.42M | -70.0% |
| FY2022 | 2022-12-31 | 14.7M | +5.4% |
| FY2021 | 2021-12-31 | 13.95M | — |
Stock-Based Compensation vs competitors
How PRTC compares with its peers on the latest reported figures
- PRTC's FY2025 stock-based compensation of $8.22M is the 9th largest of the 11 companies compared; the peer median is $13.88M.
- Its year-over-year change of -64.0% is the 10th highest of 11, against a peer median of -6.5%.
- Stock-based compensation amounts to 176.5% of revenue for PRTC, versus a peer median of 31.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $36.4M | -7.4% | +94.0% | 492.0% |
| LTM Mar 2026 | $35.22M | -20.0% | +6.1% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $27.96M | -33.3% | +53.3% | — |
| LTM Mar 2026 | $18.73M | +52.9% | +30.9% | — | |
| LTM Mar 2026 | $15.14M | -5.7% | +6.3% | 16.3% | |
| LTM Mar 2026 | $12.63M | +26.4% | -48.5% | 16.0% | |
| LTM Mar 2026 | $12.56M | +183.6% | +171.6% | — | |
| LTM Mar 2026 | $10.98M | +14.3% | -1.3% | 592.7% | |
| FY2025 | $8.22M | -64.0% | -17.6% | 176.5% | |
| LTM Mar 2026 | $4.71M | -8.3% | +3.5% | 31.8% | |
| LTM Mar 2026 | $3.41M | -69.9% | +124.6% | — | |
| Peer median (excluding PRTC) | $13.88M | -6.5% | +18.6% | 31.8% | |
Competitors are the stored peer set for PRTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (62.71M) | (37.07M) | (65.7M) | 27.78M | (110M) |
| Depreciation & Amortization | 7.29M | 8.89M | 4.93M | 3.57M | 3.36M |
| Deferred Income Tax | (112.61M) | (70.12M) | 0 | 0 | 0 |
| Stock-Based Compensation | 13.95M | 14.7M | 4.42M | 22.85M | 8.22M |
| Change in Working Capital | 861K | 15.92M | 17.52M | (10.24M) | (3.13M) |
| Accounts Receivables | (617K) | (7.73M) | 9.75M | 629K | (236.55K) |
| Inventory | (103K) | 0 | 0 | 0 | 0 |
| Accounts Payables | 8.34M | 22.03M | 3.84M | (9.7M) | (1.03M) |
| Other Working Capital | (6.76M) | 1.62M | 3.93M | (1.17M) | (1.87M) |
| Other Non-Cash Items | (5.05M) | (111.12M) | (67.09M) | (178.34M) | 16.22M |
| Operating Cash Flow | (158.27M) | (178.79M) | (105.92M) | (134.37M) | (85.33M) |
| Capital Expenditures | (5.66M) | (2.18M) | (245K) | (11K) | (6.01K) |
| Acquisitions (Net) | 321K | (20.44M) | (13.78M) | (105.97M) | 269.63K |
| Purchases of Investments | (500K) | (268.73M) | (195.71M) | (309.6M) | (85.29M) |
| Sales of Investments | 218.13M | 183.71M | 277.87M | 656.22M | 148.41M |
| Other Investing Activities | (14.91M) | 416K | 865K | 255K | 49.11K |
| Investing Cash Flow | 197.38M | (107.22M) | 68.99M | 240.89M | 63.44M |
| Debt Repayment | 2.22M | 393K | (3.34M) | (3.39M) | 0 |
| Common Stock Issued | 38.03M | 332K | 1.15M | 895K | 106.25K |
| Common Stock Repurchased | (13.33M) | (26.49M) | (19.65M) | (107.56M) | (2.06M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 33.84M | (4.07M) | 99.98M | 93.1M | (4.39M) |
| Financing Cash Flow | 22.73M | (29.83M) | 78.14M | (16.96M) | (6.34M) |
| Effect of Forex Changes | (1K) | 0 | 0 | 0 | 19.83K |
| Net Change in Cash | 61.83M | (315.84M) | 41.22M | 89.56M | (28.22M) |
| Free Cash Flow | (163.94M) | (180.97M) | (106.16M) | (134.38M) | (85.34M) |
PureTech Health plc
NASDAQ:PRTC
Intrinsic Alpha fair value
Locked
Current Price
$17.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.